SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’

An official website of the United States government

Here's how you know

Official websites use .mil

A .mil website belongs to an official U.S. Department of Defense organization in the United States.

Secure .mil websites use HTTPS

A lock () or https:// means you’ve safely connected to the .mil website. Share sensitive information only on official, secure websites.

JPEO-CBRND Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

JPEO-CBRND

Search Joint Program Executive Office for Chemical, Biological Defense (JPEO-CBRND):

Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics.

PHOTO INFORMATION

Download

Details

201116-A-HZ730-1019

Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics. (U.S. Army photo by Jason W. Edwards)

https://finance.yahoo.com/news/sab-biotherapeutics-doses-first-patient-200200245.html

COVID -19

News Search

News Archive - Search by Year and Month

2024 (24)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

News Archive - Search by Year and Month

JPEO-CBRND Press Kit

JPEO-CBRND Public Affairs Office